All of us who are taking medicine which ensures that we can live with HIV know what it is like to have to take at least one pill a day – every day. I am fortunate that Eviplera® has been working for me for over a year, but there are many others who are still taking a combination of drugs in many different pills.
Today there is further good news on the drug development front. ViiV Healthcare today announced that they have made a European regulatory submission for a single-table regimen containing dolutegravir with abacavir and lamivudine for people living with HIV. Dolutegravir is used in the US and is known as Tivicay®.
Dr John Pottage, Chief Medical Officer at ViiV Healthcare said,
People living with HIV and their doctors seek to use appropriate treatment options for the individual, while also trying to minimise the number of pills required for effective and acceptable antiretroviral treatment. This submission, together with the New Drug Application submitted to the US Food and Drug Administration, aims to make a complete dolutegravir-based regimen available for the first time in a single once-daily pill.”
I am sure that all of us will be glad to hear this news.
ViiV Healthcare is a global specialist HIV company established in November by GlaxoSmithKline and Pfizer dedicated to delivering advances in treatment and care for people living with HIV. Shionogi joined as a 10% shareholder in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and new HIV medicines, as well as support communities affected by HIV. More information on the company can be found on its website: www.viivhealthcare.com.